Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial
Lu et al., eClinicalMedicine, doi:10.1016/j.eclinm.2024.102582
https://c19early.org/lu5.html